UNC-School of Medicine: Drug in OUtMATCH Clinical Trial FDA-Approved for the Reduction of Allergic Reactions From Accidental Food Exposures
February 26, 2024
February 26, 2024
CHAPEL HILL, North Carolina, Feb. 26 (TNSres) -- The University of North Carolina School of Medicine issued the following news release:
* * *
Stage one results from the OUtMATCH clinical trial, published in the New England Journal of Medicine, show that a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as age one could consume without an allergic reaction. Edwin Kim, MD, Corinne K . . .
* * *
Stage one results from the OUtMATCH clinical trial, published in the New England Journal of Medicine, show that a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as age one could consume without an allergic reaction. Edwin Kim, MD, Corinne K . . .